Explore the words cloud of the CAMEOS project. It provides you a very rough idea of what is the project "CAMEOS" about.
The following table provides information about the project.
UNIVERSITAIR MEDISCH CENTRUM UTRECHT
|Coordinator Country||Netherlands [NL]|
|Total cost||260˙929 €|
|EC max contribution||260˙929 € (100%)|
1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
|Duration (year-month-day)||from 2016-07-01 to 2019-06-30|
Take a look of project's partnership.
|1||UNIVERSITAIR MEDISCH CENTRUM UTRECHT||NL (UTRECHT)||coordinator||260˙929.00|
|2||BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY||US (STANFORD)||partner||0.00|
|3||THE REGENTS OF THE UNIVERSITY OF CALIFORNIA||US (OAKLAND CA)||partner||0.00|
Heart disease is the most significant cause of morbidity and mortality in the industrialized world, and the cause of 4 million death each year within the European Union. The prevalence of the disease is a huge burden on society estimated to cost the EU economy 60 billion annually on drug therapy, patient care, and loss in productivity. Nonetheless, despite the latest advances in research much remains to be learn about pharmacological treatments in cardiovascular disease. Recently, the development of induced-pluripotent stem cells (iPSC) technology has led to the creation of ‘patient-in-a-dish” models through the utilization of iPSC-derived cardiomyocytes. In this setting, a high-throughput screening approach can applied to find novel therapeutic interventions and detect the cardiotoxicity of drugs. However, the limitation of the current format centers on the lack of phenotypic cardiomcyoytes maturity. Consequently, these in vitro models often fail to recapitulate relevant physiological traits. The aim of CAMEOS is to develop a cardiac microtissue with superior physiological relevance for in vitro high-throughput screening. I will employ state-of-the-art cardiac tissue engineering principles to improve the maturation of iPSC-cardiomyocyte. These will be scaled-down, by the development of microtissue, for utilization in high-throughput 96-well plate format, and will be validated by their pharmacological responses and iPS-disease modeling potential. I will apply the developed microtissue to model a complex disease mutation, phospholamban (PLN) R14del, for which the pathology is poorly understood and no cure is available. In the microtissue, I will be able to study the physiological implication of the mutation and perform a high-content screens in attempt to find novel therapeutic targets.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAMEOS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "CAMEOS" are provided by the European Opendata Portal: CORDIS opendata.
Shaping the European Migration Policy: the role of the security industryRead More
Natural Product-Inspired Therapies for Leishmaniasis and Chagas DiseaseRead More
Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and IconographyRead More